Seagen trading 12% higher as financial results exceed estimates

16 February 2023

US biotech Seagen (Nasdaq: SGEN) was trading 12% higher early in Thursday’s trading after its latest financial results beat estimates.

The company’s revenue for the fourth quarter of 2022 rose by 23% to $528.15 million, beating the analyst consensus of $479.84 million. Seagen posted a loss per share of $0.80, far better than the expected loss per share of $1.03 and an improvement on the loss of $0.95 of the same period a year earlier.

Analyst SVB Securities noted that Seagen beat consensus estimates across its major products Padcev (enfortumab vedotin-ejfv), Tukysa (tucatinib), and Adcetris (brentuximab vedotin).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK